x

Rechercher un essai clinique

* (*) Champ obligatoire

257 Résultat(s)

Trier par

Essai en cours de recrutement = Essai en cours de recrutement; Essai en cours = Essai en cours; Financé par un membre IRDiRC =

Essai(s) clinique(s) national(aux)

ALLEMAGNE

Baden-Württemberg
ULM

Essai en cours de recrutementEssai en coursEMAA: Efficacy and Safety of Eltrombopag in Patients with Acquired Moderate Aplastic Anemia who are treated with Ciclosporin A (Phase II/III) - DE
DRK Baden-Württemberg/ Hessen
Institut für Klinische Transfusionsmedizin und Immungenetik Ulm

ALLEMAGNE

Sachsen
DRESDEN

Essai en coursA phase III, multicenter, randomised, double-blind, placebo-controlled study of Darbepoetin Alfa for the treatment of anaemic subjects with low or intermediate-1 risk Myelodysplastic Syndrome - DE
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation

ALLEMAGNE

Baden-Württemberg
HEIDELBERG

Essai en coursMPN-SG 01-09 (MPN Pomalidomide): Multicenter Phase II Study with Pomalidomide in patients with Myeloproliferative Neoplasms in fibrotic Stage
Nationales Centrum für Tumorerkrankungen (NCT)
Nationales Centrum für Tumorerkrankungen (CCC) Heidelberg

ALLEMAGNE

Baden-Württemberg
ULM

ALLEMAGNE

Hamburg
HAMBURG

Essai en cours de recrutementEssai en coursRuxolitinib versus allogeneic stem cell transplantation for patients with myelofibrosis according to donor availability: A prospective phase II trial (MMM 02 study) - DE
UKE - Universitätsklinikum Hamburg-Eppendorf
Interdisziplinäre Klinik und Poliklinik für Stammzelltransplantation

ALLEMAGNE

Nordrhein-Westfalen
AACHEN

ALLEMAGNE

Nordrhein-Westfalen
MINDEN

Essai en coursJHTB(a): A Phase 2 Study of LY2784544 in Patients With Myeloproliferative Neoplasms - DE
Johannes Wesling Klinikum Minden
Klinik für Hämatologie, Onkologie und Palliativmedizin

AUTRICHE

WIEN
WIEN

Essai en coursA Phase 2 Study of LY2784544 in Patients with Myeloproliferative Neoplasms - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Hämatologie und Hämostaseologie

ESPAGNE

Madrid
ADDRESS: NOT PROVIDED - ES

ETATS-UNIS

Ohio
CINCINNATI

Essai en cours de recrutementEssai en coursFinancé par un membre IRDiRCQuercetin in Children With Fanconi Anemia; a Pilot Study (Phase 1/2) - US
Cincinnati Children's Hospital Medical Center
Department of Pediatry

FRANCE

BRETAGNE
BREST

Traitement de la splénomégalie myéloïde par le thalidomide (Phase II) - Terminé -
CHU de Brest - Hôpital de la Cavale Blanche
Laboratoire d'hématologie

FRANCE

ILE-DE-FRANCE
PARIS

VPACS : Ventilation à pression positive non invasive pour la prévention du syndrome respiratoire aigu dans la drépanocytose avec crise vaso-occlusive et traitement morphinique
Hôpital Necker-Enfants Malades
Service de Réanimation et unités de soins continus médico-chirurgicale pédiatriques

FRANCE

OUTRE-MER
FORT DE FRANCE

PAYS-BAS

Gelderland
NIJMEGEN

PAYS-BAS

Noord-Holland
AMSTERDAM

Essai en coursMicrovascular Damage in Sickle Cell Disease
Amsterdam UMC, locatie AMC
Afdeling Hematologie

ROYAUME-UNI

Greater London
LONDON

ROYAUME-UNI

Greater Manchester
ADDRESS: NOT PROVIDED - UK

ROYAUME-UNI

Greater Manchester
ADDRESS: NOT PROVIDED - UK

ALLEMAGNE

Baden-Württemberg
HEIDELBERG

An open-label, multicentre controlled clinical trial of Eculizumab in adult patients with plasma therapy-resistant Atypical Hemolytic-Uremic Syndrome (aHUS) (Phase II) - DE
Zentrum für Kinder- und Jugendmedizin - Angelika-Lautenschläger-Klinik
Klinik für Kinderheilkunde I - Sektion Pädiatrische Nephrologie

ALLEMAGNE

Baden-Württemberg
HEIDELBERG

An open-label, multicentre controlled clinical trial of Eculizumab in adult patients with plasma therapy-sensitive Atypical Hemolytic-Uremic Syndrome (aHUS) (Phase II) - DE
Zentrum für Kinder- und Jugendmedizin - Angelika-Lautenschläger-Klinik
Klinik für Kinderheilkunde I - Sektion Pädiatrische Nephrologie

ALLEMAGNE

Baden-Württemberg
HEIDELBERG

An open-label, multicentre clinical trial of Eculizumab in pediatric patients with Atypical Hemolytic-Uremic Syndrome (aHUS) (Phase II) - DE- Completed
Zentrum für Kinder- und Jugendmedizin - Angelika-Lautenschläger-Klinik
Klinik für Kinderheilkunde I - Sektion Pädiatrische Nephrologie

AUTRICHE

WIEN
ADDRESS: NOT PROVIDED - AT

ESPAGNE

Cataluña
BARCELONA

ITALIE

EMILIA ROMAGNA
FERRARA

Essai en coursAn Open-Label Extension Study to Evaluate the Long-Term Effects of ACE-536 in Patients With beta-Thalassemia Previously Enrolled in Study A536-04
A.O.U. di Ferrara - Nuovo Ospedale S.Anna - Sede di Cona
Day Hospital della Talassemia e delle Emoglobinopatie

ITALIE

LAZIO
ROMA

Phase 2, Double-Blind, Placebo Controlled Clinical Trial of EPI-743 in Subjects With Cobalamin C Defect
IRCCS Ospedale Pediatrico Bambino Gesù - SEDE SAN PAOLO
U.O.C. di Patologia Metabolica

ITALIE

LOMBARDIA
MILANO

Essai en cours de recrutementEssai en coursAn open-label, multi-center clinical trial of eculizumab in pediatric patients with atypical hemolytic-uremic syndrome (aHUS) (Phase II) - IT
IRCCS Ca' Granda - Ospedale Maggiore Policlinico - Clinica Pediatrica De Marchi
Centro per la Cura e lo Studio della Sindrome Emolitico Uremica (Center for HUS Control)

ITALIE

LOMBARDIA
PAVIA

Eltrombopag per le trombocitopenie ereditarie
Fondazione IRCCS Policlinico San Matteo
Clinica Medica III

PAYS-BAS

Gelderland
NIJMEGEN

ROYAUME-UNI

Greater London
LONDON

Essai en coursAn open-label, multi-center clinical trial of eculizumab in pediatric patients with atypical hemolytic-uremic syndrome (aHUS) (Phase II) - UK
University College London Hospitals, NHS Foundation Trust
Renal Office - Consultant Paediatric Nephrologist

ROYAUME-UNI

Tyne & Wear
NEWCASTLE UPON TYNE

An open-label, multi-center controlled clinical trial of eculizumab in adult patients with plasma therapy-resistant Atypical Hemolytic-Uremic Syndrome (aHUS) (Phase II) - UK
Newcastle upon Tyne Hospitals NHS Trust
John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine

ROYAUME-UNI

Tyne & Wear
NEWCASTLE UPON TYNE

An open-label, multi-center controlled clinical trial of eculizumab in adolescent patients with plasma therapy-resistant Atypical Hemolytic-Uremic Syndrome (aHUS) (Phase II) - UK
Newcastle upon Tyne Hospitals NHS Trust
John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine

ROYAUME-UNI

Tyne & Wear
NEWCASTLE UPON TYNE

An open-label, multi-center controlled clinical trial of eculizumab in adult patients with plasma therapy-sensitive Atypical Hemolytic-Uremic Syndrome (aHUS) (Phase II) - UK
Newcastle upon Tyne Hospitals NHS Trust
John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine

ROYAUME-UNI

Tyne & Wear
NEWCASTLE UPON TYNE

An open-label, multi-center controlled clinical trial of eculizumab in adolescent patients with plasma therapy-sensitive Atypical Hemolytic-Uremic Syndrome (aHUS) (Phase II) - UK
Newcastle upon Tyne Hospitals NHS Trust
John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine

ITALIE

LOMBARDIA
BRESCIA

Essai(s) clinique(s) multinational(aux)

ESPAGNE

Madrid
MADRID

Essai en coursFinancé par un membre IRDiRCEUROFANCOLEN: Phase I/II Gene Therapy Trial of Fanconi anemia patients with a new Orphan Drug consisting of a lentiviral vector carrying the FANCA gene: A Coordinated International Action
CIEMAT - Centro de Investigaciones Energéticas Medioambientales y Tecnológicas
Terapias innovadoras en el sistema hematopoyético